Willner & Heller LLC Has $762,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Willner & Heller LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 81.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,925 shares of the medical research company's stock after buying an additional 1,317 shares during the period. Willner & Heller LLC's holdings in Amgen were worth $762,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Ascent Group LLC increased its holdings in Amgen by 0.3% during the 2nd quarter. Ascent Group LLC now owns 10,949 shares of the medical research company's stock worth $3,421,000 after purchasing an additional 31 shares in the last quarter. Cadinha & Co. LLC grew its holdings in shares of Amgen by 0.6% during the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company's stock worth $1,678,000 after buying an additional 32 shares in the last quarter. Lansing Street Advisors raised its position in Amgen by 1.3% in the 3rd quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company's stock valued at $832,000 after buying an additional 32 shares during the last quarter. Unionview LLC lifted its stake in Amgen by 3.8% in the 3rd quarter. Unionview LLC now owns 876 shares of the medical research company's stock valued at $282,000 after acquiring an additional 32 shares in the last quarter. Finally, Traveka Wealth LLC boosted its position in Amgen by 4.3% during the 3rd quarter. Traveka Wealth LLC now owns 807 shares of the medical research company's stock worth $260,000 after acquiring an additional 33 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AMGN. Citigroup dropped their target price on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Truist Financial dropped their price objective on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Bank of America reissued an "underperform" rating and issued a $256.00 target price on shares of Amgen in a research note on Tuesday, December 10th. Sanford C. Bernstein began coverage on shares of Amgen in a research report on Thursday, October 17th. They set an "outperform" rating and a $380.00 price target on the stock. Finally, StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $314.91.

Amgen Price Performance

AMGN stock traded up $2.68 during midday trading on Monday, reaching $272.11. 3,244,015 shares of the stock were exchanged, compared to its average volume of 3,140,853. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a fifty day moving average price of $273.95 and a 200 day moving average price of $307.18. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a market capitalization of $146.27 billion, a PE ratio of 34.84, a P/E/G ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period last year, the company earned $4.96 EPS. The firm's revenue was up 23.2% compared to the same quarter last year. As a group, analysts expect that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a positive change from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.50%. Amgen's dividend payout ratio (DPR) is presently 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.